Consolidated revenue for the quarter at Rs 2,247 crore grew by 35% over a year-ago period. On the operating front, EBITDA increased by 62.2% YoY to Rs 292.4 crore with margin expansion of 221 bps for the quarter. Company has an exceptional gain of Rs 37.87 crore against loss of Rs 12.8 crore YoY. 2/13 Biocon: The biopharmaceutical company has fulfilled its payment obligation and has fully redeemed the commercial papers of Rs 2,250 crore. The bid project cost by HG Infra is Rs 466.11 crore and the construction period is 30 months.
Continue reading...